Pfizer said Friday an early analysis showed a two-dose regimen of its COVID vaccine wasn't effective for some young kids, and it will amend an ongoing study to test a third dose.
"Compared to the 16- to 25-year-old population in which high efficacy was demonstrated, non-inferiority was met for the 6- to 24-month-old population but not for the 2- to under 5-year-old population in this analysis," Pfizer said in a statement.
The company will now look at a third dose two months after the second dose in kids ages 6 months to 5 years.
Pfizer said if the three-dose regimen works, it expects to submit to regulators for emergency authorization in the first half of next year.
Get Tri-state area news and weather forecasts to your inbox. Sign up for NBC New York newsletters.
Copyright NBC New York
